MagVenture ISM 2026: Day 1 Highlights and the Future of Precision TMS

The MagVenture International Sales Meeting (ISM) 2026 kicked off with a powerful vision for the future of non-invasive neuromodulation. The first day brought together global partners to explore the latest clinical and technical milestones that will define the coming year. Key Day 1 Highlights:. The T65 Coil Reveal: Partners received their first technical deep-dive into the T65 liquid-cooled coil. This innovation is MagVenture's lightest cooled coil, designed to handle both motor threshold (MT) determination and full treatment protocols in one seamless workflow., Adolescent MDD Strategy: Following the recent FDA clearance for ages 15-21 , sessions focused on the urgent clinical need for adolescent depression treatments and how to support pediatric psychiatric clinics with this new indication., Neuronavigation Mastery: A spotlight on the MagVenture TMS Atlas™ demonstrated how integrated navigation is moving from a research luxury to a clinical standard for ensuring repeatable, high-precision targeting., Global Sales Excellence: Leadership outlined the 2026 roadmap, focusing on increasing access to TMS therapy in new international markets and strengthening technical support for existing hospital networks. The energy of Day 1 set a high standard for the rest of the meeting, emphasizing MagVenture's role as a driver of evidence-based innovation in mental health.